Bausch Health (BHC) Q1 Earnings and Revenues Lag Estimates

Core Viewpoint - Bausch Health (BHC) reported quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of$0.83 per share, indicating an earnings surprise of -28.92% [1] Financial Performance - The company posted revenues of $2.26 billion for the quarter ended March 2025, which was below the Zacks Consensus Estimate by 0.54$2.15 billion a year ago [2] - Over the last four quarters, Bausch has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Bausch shares have declined approximately 31.6% since the beginning of the year, contrasting with the S&P 500's decline of -5.5% [3] - The current Zacks Rank for Bausch is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.05 on revenues of$2.46 billion, and for the current fiscal year, it is $4.26 on revenues of$9.92 billion [7] - The estimate revisions trend for Bausch is mixed, and changes in estimates for the coming quarters and current fiscal year are anticipated following the recent earnings report [6][7] Industry Context - The Medical - Generic Drugs industry, to which Bausch belongs, is currently in the top 20% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]